Educational evidence review ·Go Regen Pain
Evidence Review: Red Light Therapy for Pain by Condition
Evidence last reviewed: September 22, 2026. This page is an educational evidence review, not a treatment guide.
Photobiomodulation (PBM), sometimes marketed as red-light or red/near-infrared-light therapy, has been studied for several pain-related conditions. The evidence is condition-specific: results from an exercise-recovery study, for example, should not be treated as proof that a consumer device relieves chronic joint, nerve, or spine pain.
Many studies use red or near-infrared wavelengths, including wavelengths around 630–660 nm and 800–850 nm. Wavelength alone does not reproduce a trial. To compare a device with a study, readers need the irradiance at the treatment surface, treatment area, energy per point or session, contact/distance, treatment frequency, and total treatment course. Our red light device output data documents how often those figures are missing from product pages. Safe-use boundaries are covered in the home-use safety guidance.
Keep these separate
- Evidence for PBM in a diagnosed pain condition
- Evidence for exercise performance or recovery in healthy people
- Manufacturer specifications for a named consumer device
- This site’s commercial relationship with POLY Go Regen
Not interchangeable
- A performance or fatigue study is not pain-treatment evidence
- Neck-pain reviews do not establish a home-use protocol
- A wavelength or 5-minute timer is not a trial dose
- FDA registration is not clearance, approval, or proof of benefit
Where evidence is more established
Neck pain. Systematic reviews of low-level laser therapy have reported reduced pain after treatment in acute neck pain and benefits extending to follow-up in some chronic-neck-pain trials. However, protocols, device types, comparators, and study quality differ, so this literature does not establish one universal wavelength, irradiance, or home-use schedule.
Exercise performance and recovery. Separate systematic-review evidence in healthy people suggests that PBM used before exercise may improve some performance and fatigue-related outcomes. This is not the same as evidence for treating a pain diagnosis, and the certainty of evidence ranges from very low to moderate.
Tendinopathy and temporomandibular disorders. Evidence is mixed. Some controlled trials and reviews report pain or function benefits, but findings vary by condition, protocol, comparator, and treatment combination. Achilles-tendinopathy evidence should not be generalized from lateral epicondylitis or other tendinopathies; one Achilles-focused review found no significant pain effect.
Wavelength and dose
Many PBM studies use red and near-infrared wavelengths, commonly including approximately 630–660 nm and 800–850 nm. Red is generally used for more superficial targets, while near-infrared light tends to reach deeper, but neither wavelength guarantees a dose at a specific tissue depth. Tissue type, pigmentation, contact, angle, treatment distance, and device optics all affect the delivered dose.
Published PBM protocols vary substantially in irradiance, spot size, energy per point, treatment area, contact technique, session frequency, and total treatment course. A stated wavelength or session time alone is not enough to reproduce a trial protocol. Therefore, a product’s wavelength or timer setting alone is not enough to establish that it matches a positive clinical study.
| Needed to match a study | Why it matters |
|---|---|
| Wavelength or spectral output per channel | Clinical protocols are not limited to one pair of bands |
| Irradiance at the treatment surface | Emitter ratings are not the dose at the skin |
| Spot size / treatment area | Energy is spread over the field that is actually treated |
| Energy per point, total energy, and site count | Reviews often report joules per point or muscle group, not minutes alone |
| Contact vs non-contact and distance | Geometry changes the delivered dose |
| Frequency, total sessions, and the condition studied | A course of care is not a single session |
| Source type (laser, LED array, cluster probe) | Output and beam characteristics differ by design |
Where evidence remains uncertain
Substantial heterogeneity in diagnoses, wavelengths, dose reporting, comparators, and outcomes limits how confidently results can be pooled or generalized across devices and conditions.
Nonspecific low-back pain. A Cochrane review found small, heterogeneous studies with varying populations, protocols, and comparison groups, and concluded that the evidence was insufficient for firm conclusions about clinical effectiveness. Readers should not assume that results from neck pain, exercise recovery, or tendinopathy apply to low-back pain. A current review should be cited before any claim about the number or adequacy of sham-controlled trials.
Diabetic peripheral neuropathy. Small and methodologically varied studies suggest possible benefit for neuropathic pain and nerve-conduction measures, but the evidence base remains limited and larger, rigorously controlled trials are needed.
Post-herpetic neuralgia. This page does not make a condition-specific claim. It should not be combined with diabetic peripheral neuropathy under one evidence statement.
Comparing a device with the evidence
Disclosure: this site sells and links to POLY equipment, including the POLY Go Regen Pain. That commercial relationship is separate from the evidence summarized above.
According to manufacturer materials, the POLY Go Regen Pain model is described as using 633 nm and 850 nm light and five-minute treatment increments per selected area. Those characteristics place it within commonly used PBM wavelength ranges, but they do not by themselves establish irradiance at the skin, energy delivered per wavelength, treatment-field size, or equivalence to any clinical protocol. Verify all current specifications against the manufacturer’s labeling or manual before making a purchasing recommendation. See the measured-output audit for what product pages typically omit, and review the POLY Go Regen option for the figures this page cannot invent.
Regulatory status
FDA 510(k) clearance is not FDA approval or a guarantee of clinical benefit for every pain condition. It means FDA has found a device substantially equivalent to a legally marketed predicate for its specified intended use, allowing U.S. commercial distribution. FDA establishment registration or device listing is an administrative requirement; it is not equivalent to clearance, approval, certification, or an efficacy determination. IEC testing must name the exact standard, edition, laboratory or certifier, model, and scope. “IEC certified” alone is not enough.
We have not independently confirmed the U.S. regulatory status of this specific POLY Go Regen Pain model; request documentation directly from the manufacturer or distributor. We did not identify an FDA 510(k) clearance number or FDA database record that we could confidently match to this model as of September 22, 2026. That is not evidence that no clearance exists; request the manufacturer’s clearance number, labeling, and intended-use statement.
Frequently asked questions
Does red-light therapy work for pain?
The best answer is sometimes, for some conditions and protocols—but not with the same certainty across all pain diagnoses. Evidence is more developed for some musculoskeletal applications, including neck pain, while evidence for low-back pain and neuropathic conditions remains less certain or more limited. The practical question is not whether a device emits a familiar wavelength; it is whether its documented output, treatment geometry, and instructions plausibly match evidence for the specific condition being considered.
The World Association for Laser Therapy publishes dose recommendations for some musculoskeletal applications, but those tables should be treated as condition- and protocol-specific guidance rather than a universal consumer-device prescription. Before spending money on a device, check red light device output data to see what is actually published.
Review the POLY Go Regen option
This page identifies where evidence is stronger, mixed, or limited so a spending or recommendation decision can rest on research rather than marketing copy. Manufacturer specifications and this site’s product listing are not clinical-protocol evidence. review the POLY Go Regen option has the figures this page cannot invent.
Main Menu